SOPHiA GENETICS SA (SOPH) shareholders
Close on Nov 17, 2026Market cap $510.22MP/E –Yield –
Ownership
Who owns SOPHiA GENETICS's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Generation Investment Management LLP Joint filing with Generation IM Sustainable Solutions GP III Limited (10.22%), Generation IM Sustainable Solutions Fund III, L.P. (10.22%) | 6,789,560 | 10.22% | 13G (passive) amendment | Sep 30, 2024 |
| Akre Capital Management, LLC Joint filing with Braddock Partners Offshore, LP (5.60%), Braddock Capital Offshore, LLC (5.60%) | 3,719,140 | 5.60% | 13G (passive) | Jun 20, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jurgi Camblong | Executive Chairman, Director | 3,378,650 | 4.93% | Nov 12, 2026 |
| Ross Muken | Chief Executive Officer, Director | 880,391 | 1.29% | Nov 9, 2026 |
| Well Daan Van | Chief Legal Officer | 330,081 | 0.48% | Nov 17, 2026 |
| Zhenyu Xu | Chief Scientific Officer | 537,493 | 0.78% | Nov 16, 2026 |
| Philippe Menu | Chief Medical Officer | 190,993 | 0.28% | Nov 16, 2026 |
| George Cardoza | Chief Financial Officer | 326,726 | 0.48% | Nov 9, 2026 |
| Abhimanyu Verma | Chief Technology Officer | 166,887 | 0.24% | Oct 7, 2026 |
| Manuela Valente | Chief People Officer | 206,210 | 0.30% | Oct 7, 2026 |
| Kevin Puylaert | Chief Sales Officer | 147,732 | 0.22% | Oct 7, 2026 |
| Kathy L. Hibbs | Director | 90,742 | 0.13% | Nov 12, 2026 |
| Troy Cox | Director | 328,743 | 0.48% | Jun 22, 2026 |
| Didier Hirsch | Director | 240,220 | 0.35% | Jun 22, 2026 |
| Vincent Ossipow | Director | 522,860 | 0.76% | Jun 22, 2026 |
| Jean-Michel Cossery | Director | 206,212 | 0.30% | Jun 22, 2026 |
| Tomer Berkovitz | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Well Daan Van Chief Legal Officer | Nov 16, 2026 | Sale(10b5-1 plan) | −1,224 | $7.73 | $9.46K | 330,081 |
| Zhenyu Xu Chief Scientific Officer | Nov 13, 2026 | Sale(10b5-1 plan) | −4,000 | $7.96 | $31.82K | 537,493 |
| Philippe Menu Chief Medical Officer | Nov 12, 2026 | Sale(10b5-1 plan) | −5,000 | $7.68 | $38.40K | 190,993 |
| Kathy L. Hibbs Director | Nov 10, 2026 | Sale(10b5-1 plan) | −6,250 | $7.76 | $48.48K | 90,742 |
| Jurgi Camblong Executive Chairman, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −8,500 | $7.76 | $65.95K | 3,378,650 |
| Well Daan Van Chief Legal Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −1,411 | $7.44 | $10.49K | 331,305 |
| Ross Muken Chief Executive Officer, Director | Nov 6, 2026 | Buy | +20,000 | $6.86 | $137.19K | 680,391 |
| George Cardoza Chief Financial Officer | Nov 6, 2026 | Buy | +20,000 | $7.06 | $141.20K | 326,726 |
| Zhenyu Xu Chief Scientific Officer | Oct 13, 2026 | Sale(10b5-1 plan) | −4,000 | $7.18 | $28.73K | 541,493 |
| Philippe Menu Chief Medical Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −5,000 | $7.26 | $36.30K | 195,993 |
| Jurgi Camblong Executive Chairman, Director | Oct 12, 2026 | Sale(10b5-1 plan) | −8,500 | $7.26 | $61.67K | 3,387,150 |
| Well Daan Van Chief Legal Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −6,168 | $8.12 | $50.10K | 332,716 |
| Manuela Valente Chief People Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −4,240 | $8.13 | $34.49K | 206,210 |
| Abhimanyu Verma Chief Technology Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −5,284 | $8.12 | $42.93K | 166,887 |
| Kevin Puylaert Chief Sales Officer | Oct 5, 2026 | Sale | −31 | $7.92 | $246 | 147,732 |
| Kevin Puylaert Chief Sales Officer | Oct 5, 2026 | Sale | −185 | $8.06 | $1.49K | 147,763 |
| George Cardoza Chief Financial Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −1,592 | $8.10 | $12.90K | 306,726 |
| Philippe Menu Chief Medical Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −7,394 | $8.13 | $60.10K | 200,993 |
| Jurgi Camblong Executive Chairman, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −40,172 | $8.13 | $326.53K | 3,395,650 |
| Zhenyu Xu Chief Scientific Officer | Oct 5, 2026 | Sale(10b5-1 plan) | −7,394 | $8.12 | $60.07K | 545,493 |
| Ross Muken Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −9,838 | $8.13 | $79.97K | 660,391 |
| George Cardoza Chief Financial Officer | Sep 21, 2026 | Sale(10b5-1 plan) | −774 | $8.33 | $6.45K | 308,318 |
| Ross Muken Chief Executive Officer, Director | Sep 21, 2026 | Sale(10b5-1 plan) | −422 | $8.33 | $3.52K | 670,229 |
| Zhenyu Xu Chief Scientific Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −4,000 | $7.88 | $31.52K | 552,887 |
| Philippe Menu Chief Medical Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −5,000 | $7.88 | $39.40K | 208,387 |
| Well Daan Van Chief Legal Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −6,168 | $7.63 | $47.06K | 338,884 |
| Jurgi Camblong Executive Chairman, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −8,500 | $7.66 | $65.11K | 3,435,822 |
| Kathy L. Hibbs Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,250 | $8.13 | $50.81K | 96,992 |
| Zhenyu Xu Chief Scientific Officer | Aug 27, 2026 | Sale(10b5-1 plan) | −10,000 | $8.91 | $89.10K | 556,887 |
| Philippe Menu Chief Medical Officer | Aug 25, 2026 | Sale(10b5-1 plan) | −5,000 | $8.68 | $43.40K | 213,387 |
| Kathy L. Hibbs Director | Aug 25, 2026 | Sale(10b5-1 plan) | −6,250 | $8.68 | $54.25K | 103,242 |
| Abhimanyu Verma Chief Technology Officer | Aug 24, 2026 | Sale(10b5-1 plan) | −5,000 | $8.80 | $44.00K | 172,171 |
| Zhenyu Xu Chief Scientific Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −5,408 | $8.40 | $45.43K | 566,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 20, 2026 | Sale(10b5-1 plan) | −4,592 | $8.41 | $38.62K | 572,295 |
| Abhimanyu Verma Chief Technology Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −5,000 | $8.20 | $41.00K | 177,171 |
| Manuela Valente Chief People Officer | Aug 19, 2026 | Option exercise | +10,000 | $3.20 | $32.00K | 220,450 |
| Manuela Valente Chief People Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −10,000 | $7.94 | $79.40K | 210,450 |
| Zhenyu Xu Chief Scientific Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −10,000 | $7.94 | $79.40K | 576,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −4,000 | $7.52 | $30.08K | 586,887 |
| Philippe Menu Chief Medical Officer | Aug 12, 2026 | Sale(10b5-1 plan) | −5,000 | $7.52 | $37.60K | 218,387 |
| Jurgi Camblong Executive Chairman, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −8,500 | $7.61 | $64.69K | 3,444,322 |
| Abhimanyu Verma Chief Technology Officer | Aug 7, 2026 | Sale(10b5-1 plan) | −5,000 | $7.60 | $38.00K | 182,171 |
| Jurgi Camblong Executive Chairman, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −20,000 | $7.23 | $144.60K | 3,452,822 |
| Zhenyu Xu Chief Scientific Officer | Aug 7, 2026 | Option exercise | +7,000 | $3.28 | $22.96K | 607,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 7, 2026 | Sale(10b5-1 plan) | −7,000 | $7.02 | $49.14K | 600,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 7, 2026 | Sale(10b5-1 plan) | −10,000 | $7.48 | $74.80K | 590,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −3,000 | $7.00 | $21.00K | 600,887 |
| Zhenyu Xu Chief Scientific Officer | Aug 5, 2026 | Option exercise | +3,000 | $3.28 | $9.84K | 603,887 |
| Jurgi Camblong Executive Chairman, Director | Aug 4, 2026 | Sale(10b5-1 plan) | −20,000 | $6.92 | $138.40K | 3,472,822 |
| Abhimanyu Verma Chief Technology Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −5,000 | $6.95 | $34.75K | 187,171 |
| Zhenyu Xu Chief Scientific Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −10,000 | $6.92 | $69.20K | 600,887 |
| Philippe Menu Chief Medical Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −5,000 | $5.66 | $28.30K | 223,387 |
| Jurgi Camblong Executive Chairman, Director | Jul 21, 2026 | Sale(10b5-1 plan) | −20,000 | $6.63 | $132.60K | 3,492,822 |
| Jurgi Camblong Executive Chairman, Director | Jul 20, 2026 | Option exercise | +4,581 | $3.16 | $14.48K | 3,517,403 |
| Jurgi Camblong Executive Chairman, Director | Jul 20, 2026 | Sale(10b5-1 plan) | −4,581 | $6.17 | $28.26K | 3,512,822 |
| Jurgi Camblong Executive Chairman, Director | Jul 20, 2026 | Sale(10b5-1 plan) | −19,800 | $6.32 | $125.14K | 3,512,822 |
| Philippe Menu Chief Medical Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −5,000 | $5.70 | $28.50K | 228,387 |
| Zhenyu Xu Chief Scientific Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −4,000 | $5.70 | $22.80K | 610,887 |
| Jurgi Camblong Executive Chairman, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −8,500 | $5.62 | $47.77K | 3,532,622 |
| Jurgi Camblong Executive Chairman, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −17,685 | $5.28 | $93.38K | 3,541,122 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SOPHiA GENETICS's stock actually held short. Settlement fails (shares not delivered on time) peaked at 126,994 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daan Guido Maria Van Well Officer | Nov 9, 2026 | 1,411 | $10.07K | Nov 9, 2026 | Restricted Stock Units |
| Jurgi Camblong Director, Officer | Oct 5, 2026 | 65,672 | $529.97K | Oct 5, 2026 | Restricted Stock Units |
| George Cardoza Officer | Oct 5, 2026 | 1,592 | $12.85K | Oct 5, 2026 | Restricted Stock Units |
| Manuela Valente Officer | Oct 5, 2026 | 4,240 | $34.22K | Oct 5, 2026 | Restricted Stock Units |
| Philippe Menu Officer | Oct 5, 2026 | 22,394 | $180.72K | Oct 5, 2026 | Restricted Stock Units |
| Ross Muken Director, Officer | Oct 5, 2026 | 9,838 | $79.39K | Oct 5, 2026 | Restricted Stock Units |
| Daan Guido Maria Van Well Officer | Oct 5, 2026 | 6,168 | $49.78K | Oct 5, 2026 | Restricted Stock Units |
| Zhenyu Xu Officer | Oct 5, 2026 | 19,394 | $156.51K | Oct 5, 2026 | Restricted Stock Units |
| George Cardoza Officer | Sep 21, 2026 | 774 | $6.34K | Sep 21, 2026 | Restricted Stock Units |
| Ross Muken Director, Officer | Sep 21, 2026 | 422 | $3.46K | Sep 21, 2026 | Restricted Stock Units |
| Daan Guido Maria Van Well Officer | Sep 11, 2026 | 6,168 | $46.94K | Sep 11, 2026 | Restricted Stock Units |
| Zhenyu Xu Officer | Aug 27, 2026 | 14,000 | $119.42K | Aug 27, 2026 | Founders Shares |
| Kathy L. Hibbs Director | Aug 25, 2026 | 18,750 | $158.44K | Aug 25, 2026 | Restricted Stock Units |
| Zhenyu Xu Officer | Aug 20, 2026 | 6,000 | $49.68K | Aug 20, 2026 | Founders Shares |
| Manuela Valente Officer | Aug 19, 2026 | 10,000 | $76.20K | Aug 19, 2026 | Exercise of Stock Options |
See a number that looks wrong?